|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
CA2436326C
(en)
|
2001-01-09 |
2012-08-14 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
|
|
WO2004000102A2
(en)
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
JP2006505546A
(ja)
|
2002-10-10 |
2006-02-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
二重特異性抗ＥｒｂＢ抗体および腫瘍治療でのその使用
|
|
US8008003B2
(en)
|
2002-11-15 |
2011-08-30 |
Genomic Health, Inc. |
Gene expression profiling of EGFR positive cancer
|
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
|
PT1687338E
(pt)
|
2003-11-07 |
2011-01-20 |
Ablynx Nv |
Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
|
|
KR101462825B1
(ko)
|
2004-05-03 |
2014-11-21 |
헤르메스 바이오사이언스, 인코포레이티드 |
약물 전달에 유용한 리포좀
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
ES2809168T3
(es)
|
2006-11-15 |
2021-03-03 |
Biofire Diagnostics Llc |
Análisis biológico autónomo de alta densidad
|
|
TW200846362A
(en)
|
2007-02-09 |
2008-12-01 |
Symphogen As |
A polyclonal antibody product
|
|
BRPI0808551B1
(pt)
|
2007-03-01 |
2022-04-05 |
Symphogen A/S |
Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
|
|
WO2009030239A1
(en)
|
2007-09-06 |
2009-03-12 |
Genmab A/S |
Novel methods and antibodies for treating cancer
|
|
WO2009036379A2
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8159931B2
(en)
|
2007-12-11 |
2012-04-17 |
Broadcom Corporation |
Orthogonal pilot code construction
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
NZ589143A
(en)
|
2008-05-14 |
2012-02-24 |
Genomic Health Inc |
Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
|
|
KR20110044905A
(ko)
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
|
WO2011132182A1
(en)
|
2010-04-18 |
2011-10-27 |
Yeda Research And Development Co. Ltd. |
MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
|
|
WO2011140254A1
(en)
|
2010-05-04 |
2011-11-10 |
Adimab, Llc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
|
EP2815765A1
(en)
|
2011-03-15 |
2014-12-24 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to ERBB pathway inhibitors
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
EP2554551A1
(en)
|
2011-08-03 |
2013-02-06 |
Fundacio Institut mar d'Investigacions Médiques (IMIM) |
Mutations in the epidermal growth factor receptor gene
|
|
WO2013138371A1
(en)
|
2012-03-12 |
2013-09-19 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
MA39599A
(fr)
|
2014-05-14 |
2016-10-05 |
Merrimack Pharmaceuticals Inc |
Dosage et administration d'agents thérapeutiques anti-egfr
|
|
EP3286219A1
(en)
|
2015-04-24 |
2018-02-28 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
|